INTRODUCTION
The global dissemination of CRKP is largely mediated by certain high-risk CRKP strains, such as those of clonal group 258 (CG258), which comprises sequence type 11 (ST11) and ST258 and closely related STs (5). Meanwhile, other high-risk clones contributing to the global spread of CRKP have also been frequently reported. One example is
IMP carbapenemase, a member of the metallo-β-lactamases capable of hydrolyzing almost all β-lactams, was first described in Japan in the 1990s (11). In 2011, our group first identified a novel IMP-38 variant in the neonatology department in our hospital (12). In this study, we examined the prevalence of blaIMP-38-harboirng
RESULTS AND DISCUSSION
Prevalence of IMP-38-producing CRKP and clinical characteristics.
In this study, 14 blaIMP-38-carrying strains were confirmed by PCR amplification and sequencing from 515 continuously collected
Notably, 13 of the 14 IMP-38-positive strains were isolated from patients with neonatal sepsis in the neonatal ward, while the remaining strain was from a patient with persistent pneumonia in the pediatric neurology ward, which is adjacent to the neonatal ward. Specific clinical characteristics are described in Table 1. All 14 patients were preterm infants and had undergone endotracheal intubation, which appeared to be one of major risk factors associated with neonatal sepsis among our patients. We suspected that the infections by IMP-38-producing CRKP might have been associated with endotracheal intubation and might have been caused either by contaminated equipment or by staff contact transmission. Previously published studies also suggested that endotracheal intubation was an independent risk factor for infections caused by multidrug-resistant
TABLE 1
Clinical features of patients carrying IMP-38-producing
Subject | Age | Sex | Specimen | Sepsis | MIC (mg/liter) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TZP | FEP | CRO | CAZ | ATM | IPM | ETP | MEM | AMK | LVX | CIP | SXT | |||||
1 | 0 | Male | Blood | Yes | 8 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
2 | 11 | Female | Ascites | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
3 | 11 | Male | Sputum | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
4 | 30 | Female | Blood | Yes | 8 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
5 | 24 | Male | Blood | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
6 | 8 | Female | Blood | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
7 | 10 | Male | Blood | Yes | 8 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
8 | 6 | Female | Endotracheal tube | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
9 | 6 | Male | Sputum | No | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
10 | 28 | Male | Stool | Yes | 64 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
11 | 15 | Male | Stool | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
12 | 11 | Male | Stool | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
13 | 30 | Female | Sputum | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≤1 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
14 | 60 | Female | Stool | Yes | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥16 | ≥8 | ≥8 | ≤2 | ≤0.25 | ≤0.25 | ≤1/19 |
a
All of the patients were cured of their infections. TZP, piperacillin-tazobactam; FEP, cefepime; CRO, ceftriaxone; CAZ, ceftazidime; ATM, aztreonam; IPM, imipenem; ETP, ertapenem; MEM, meropenem; AMK, amikacin; LVX, levofloxacin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole.
Antibiotic susceptibilities and molecular detection.
All 14 isolates exhibited susceptibility to amikacin, levofloxacin, ciprofloxacin, and trimethoprim-sulfamethoxazole but showed resistance to cefepime, ceftriaxone, ceftazidime, aztreonam, ertapenem, and meropenem, while 13 isolates were susceptible to imipenem (MIC ≤ 1 μg/ml). Ten isolates were resistant to piperacillin-tazobatam (Table 1).
PCR detection of carbapenemase and ESBL genes revealed that all 14 strains carried blaIMP-38, blaCTX-M-3, blaSHV-2a, blaSHV-28, and blaTEM-1. Pulsed-field gel electrophoresis (PFGE) analysis showed that these isolates shared highly similar profiles (see Fig. S1 in the supplemental material), suggesting a clonal spread of the same blaIMP-38-harboring strains.
Multilocus sequence type (MLST) analysis showed that all 14 blaIMP-38-harboring
Genomic characterization of
Strain WCGKP294 was isolated from a sputum sample from a preterm infant in 2016. The combination of PacBio SMRT and Illumina HiSeq sequencing generated the complete closure of the WCGKP294 genome. WCGKP294 harbors a 5,540,574-bp circular chromosome and two plasmids, pWCGKP294-1 and pWCGKP294-2. The WCGKP294 chromosome harbors the oqxA and oqxB genes, which have been linked to quinolone resistance; the blaSHV-28 gene, conferring cephalosporin resistance; and the fosA6 gene, which has been linked to fosfomycin resistance. Strain WCGKP294 carried the same K and O loci (KL102, associated with wzi allele 173, and O2v2) as other global ST307 strains, as well as the second putative capsule synthesis locus (Cp2) and a π-fimbria-encoding gene cluster (16). However, inspection of the chromosomal quinolone resistance-determining regions (QRDR) failed to identify amino acid substitutions at GyrA codon 83 or 87 and at ParC codon 80 or 84, which appears to be one of the major genetic differences from other global ST307 genomes (17). Previous study of 95 global ST307 genomes showed that the ParC 80I and GyrA 83I mutations were 100% conserved among all the genomes, with a small cluster of strains carrying an additional GyrA 87N mutation (17). The QRDR mining results in WCGKP294 were in agreement with our susceptibility testing results indicating that all our strains were susceptible to ciprofloxacin and levofloxacin (Table 1).
In order to describe the relationship between IMP-38-producing strain WCGKP294 and other global ST307 strains obtained from different countries and sources, a hierarchical Bayesian clustering analysis of ST307 genomes was performed (Fig. 1). Similarly to the results of a previous study (8), the analysis divided ST307 into 6 distinct clades: clades I to VI. Strain WCGKP294 was found to belong to clade V, which is distantly related to clades I to IV (the U.S. Texas clades) and clade VI (the South African OXA-181 clade). Clades I to IV and clade VI represent strains that have been locally isolated over a long period in the United States and South Africa, while the clade V is more like a global lineage and includes isolates from Australia, Brazil, Cambodia, Cameroon, China, Colombia, France, Guinea, Iran, Italy, Nepal, Netherlands, Nigeria, Norway, Pakistan, Thailand, the United Kingdom, and the United States (8).
FIG 1
Bayesian phylogenetic analysis of global ST307
Characteristics of blaIMP-38-harboring plasmid pWCGKP294-2.
WCGKP294 was found to contain two plasmids, pWCGKP294-1 and pWCGKP294-2. Plasmid pWCGKP294-1 (GenBank accession number CP046613) was found to be 237,090 bp in length and to belong to the IncFIB incompatibility group, carrying three copies of tandemly repeated IS26-blaSHV-2A-deoR-ygbJ-ygbK-fucA-IS26 composite transposon elements (see Text S1 in the supplemental material). Plasmid pWCGKP294-2 (GenBank accession number CP046614) was found to be 230,910 bp in length with GC content of 47%. Sequence analysis indicated that plasmid pWCGKP294-2 belonged to the IncHI5 incompatibility group (Fig. 2). BLAST analysis showed that pWCGKP294-2 had high similarity to blaIMP-38-harboring pA324-IMP (MF344566), recovered from a
FIG 2
Plasmid structures of pWCGKP294-2 (GenBank accession number CP046614), pA324-IMP (MF344566), and pIMP4-LL34 (CP025964). Light blue shading denotes shared regions of homology of >99% identities, while light green shading indicates reverse-oriented regions of homology. Open reading frames (ORFs) are portrayed by arrows and colored based on predicted gene function. Orange arrows indicate plasmid scaffold regions. The genes associated with the conjugation locus are indicated by green arrows, and replication-associated genes are denoted as dark blue arrows. Antimicrobial resistance genes are indicated by red arrows, while the accessory genes are indicated by yellow arrows.
In China, the main IMP type of carbapenemase was found to be IMP-4 (18, 19), which differs from IMP-38 with an amino acid substitution at Ambler position 262 (S262G, serine to glycine) (12). It is likely that IMP-38 evolved from IMP-4 from amino acid substitution. The S262G substitution was previously identified as important for substrate specificity according to studies of other IMP variants, especially IMP-6, which differs from IMP-1 by the same S262G substitution (20–22). The S262G substitution led to a reduction in the imipenem MIC but to higher levels of meropenem and doripenem resistance in IMP-6. We therefore suspected that the imipenem-susceptible but meropenem-resistant profiles found in our IMP-38-producing ST307 CRKP strains may have been due to the S262G substitution (Table 1). Further enzyme kinetic analysis is ongoing to confirm the hypothesis.
Similarly to pA324-IMP, plasmid pWCGKP294-2 had two transposons, designated Tn6381 and Tn6382. The Tn6381 transposon was located in an ARI-B island, identified as a Tn6535 derivative, while the Tn6382 transposon was within an ARI-A island, identified as a Tn1696 derivative (23). The blaIMP-38 gene was carried by a class I integron within Tn6382 with the gene cassette of blaIMP-38-qacG2-aacA4-Δcat3 on pWCGKP294-2. In addition to blaIMP-38, several antibiotic resistance genes have also been identified on pWCGKP294-2, including β-lactamase genes blaCTX-M-3 and blaTEM-1B, aminoglycoside resistance gene aacA4, and chloramphenicol resistance gene catB3. In comparison to pIMP4_LL34 and pA324-IMP, pWCGKP294-2 contained an approximately 44-kb deletion that extended from the umuD gene to a hypothetical protein gene located upstream of hns. This deleted region included the conjugation-encoding cpl, rlx, and tivF genes, which is consistent with the inability of conjugation of pWCGKP294-2 seen during the conjugation experiment (data not shown).
A recent study suggested that IncHI5-type plasmid may be another key plasmid vector contributing to the rapid transmission of carbapenemase genes (23). Similarly, our study also suggested that IncHI5 plasmids could serve as a major vector in the spread of blaIMP in Enterobacteriaceae. To understand the phylogenetic relationship of IncHI5 plasmids, we downloaded 21 additional IncHI5 plasmids from the NCBI database and constructed a phylogenetic tree based on the sequence alignment (Fig. 3). The 22 plasmids were from various strains of
FIG 3
Phylogenetic analysis of 22 IncHI5 plasmids. The tip label was annotated as follows: plasmid name, GenBank accession number, species, and carbapenemase genes. The pWCGKP249-2 plasmid sequenced in this study is highlighted in bold. Kp,
Conversely, the previous genomic epidemiological study suggested that the global ST307 strains were closely associated with blaCTX-M-15. The blaCTX-M-15 ESBL gene was found in 93.7% of the ST307 genomes (n = 89), and among them, 82 (92.1%) carried a pKPN3-307_typeA IncFIIK/IncFIBK plasmid backbone, sharing the same insertion of the ISEcp1-blaCTX-M-15 transposon within Tn3 (16). Those results also suggested that blaCTX-M-15-harboring IncFIIK/IncFIBK plasmids may have coevolved with ST307 strains over time. However, our IMP-38-producing strain, WCGKP294, does not contain blaCTX-M-15 and instead harbors another blaCTX-M-3 variant on IncHI5 plasmid pWCGKP294-2 that was found to coexist with blaIMP-38 within the same Tn6382 transposon.
In conclusion, we have reported here the identification of IMP-38-producing high-risk ST307
MATERIALS AND METHODS
Bacterial isolates and antimicrobial susceptibility testing.
Clinical isolates were collected from January 2013 to November 2016 in a tertiary care hospital in Changsha located in the middle of China. A total 515 unique CRKP isolates (one isolate per patient) were recovered from clinical specimens. MICs of 12 antimicrobial agents were determined for all 515 clinical isolates using the microdilution method, according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) (24). The study was approved by the institutional review board (IRB) at Xiangya Hospital of Central South University.
Detection of blaIMP-38 gene.
All CRKP isolates were screened for the presence of the blaIMP gene using a previously described PCR protocol (25–27). PCR amplifications were carried out on an ABI 2720 thermal cycler (Applied Biosystems, USA). The amplicons from IMP-positive strains were then sequenced to determine blaIMP-38 variants.
MLST.
MLST was performed on clinical blaIMP-38-harboring isolates using a method described previously by Diancourt et al. (27). The ST was determined using the database maintained by the MLST Web server (https://pubmlst.org/bigsdb?db=pubmlst_mlst_seqdef).
Whole-genome sequencing and bioinformatics analysis.
The genomic DNA was extracted from IMP-38-producing ST307 strain WCGKP294 using the SDS method (28). The DNA was subsequently sequenced using single-molecule sequencing (PacBio RS) and an Illumina HiSeq system. The sequencing reads were assembled using Unicycler v0.4.8 (29). The acquired antimicrobial resistance genes were identified using ResFinder 3.0 (30), and the plasmid replicons in the sequenced isolates were identified using PlasmidFinder 2 (31). A core single nucleotide polymorphism (SNP) phylogenetic tree of WCGKP294 and of 708 global ST307 isolates (from 19 countries) was constructed using a method described previously (8). The phylogenetic tree was annotated in iTOL (32). A total of 21 IncHI5 plasmids were downloaded from GenBank, followed by alignment using Mauve 2.4.0 (33). Conserved regions were extracted from Mauve alignment, and a maximum likelihood (ML) phylogenetic tree was generated using FastTree 2.1 (34).
Data availability.
The complete genome sequences of WCGKP294 were submitted to GenBank under accession numbers CP046612 to CP046614.
b Molecular Biology Research Center and Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Changsha, China
c Center for Discovery and Innovation, Hackensack-Meridian Health, Nutley, New Jersey, USA
d Hackensack Meridian School of Medicine, Seton Hall University, Nutley, New Jersey, USA
Antimicrobial Development Specialists, LLC
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Copyright © 2020 Wang et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
ABSTRACT
An emerging multidrug-resistant
IMPORTANCE We described the genome and resistome characterization of a carbapenem-resistant
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer